Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s Aricept Seen Driving 35 Percent Profit Increase For FY09

This article was originally published in PharmAsia News

Executive Summary

Eisai expects a profit increase of about 35 percent in the fiscal year just beginning, with much of the increase due to its Aricept (donepezil) to treat Alzheimer's disease. Another major Eisai sales generator is expected to be its acquisition of U.S.-based MGI Pharma and its cancer drugs. Eisai can expect a large increase in expenses for research and development, however, because of the MGI purchase. In all, Eisai's net profit for the fiscal year that began April 1 is expected to increase by 35 percent. (Click here for more - a subscription may be required

You may also be interested in...

Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition

TOKYO - Eisai announced that it "has the right" to terminate a product development and business alliance agreement for its Alzheimer's treatment Aricept (donepezil) if Pfizer acquires Wyeth

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts